NEW YORK–(BUSINESS
WIRE)–Pluristem Therapeutics Inc. (NasdaqCM: PSTI;
DAX: PJT), a bio-therapeutics Company dedicated to the
commercialization of non- personalized (allogeneic) cell
therapy products for a variety of degenerative, ischemic and
autoimmune indications, announced today that William R. Prather
RPh, MD, Pluristem’s Sr. VP of Corporate Development, will
present at the Rodman & Renshaw 10th Annual
Healthcare Conference at 2:25PM on Monday, November 10th,
2008 at the New York Palace Hotel, New York, NY.
Dr. Prather will give a 20-minute overview of
Pluristem, detailing its clinical plans, product portfolio and
strategic direction.
Mr. Zami Aberman, Pluristem's President & CEO,
stated: "We are pleased to have been invited to the Rodman &
Renshaw Conference where we will be able to showcase Pluristem
and present our unique, proprietary 3D expansion process of our
placental derived PLX cells, targeted at a variety of
indications. We will give animal trial results, which
demonstrate the potential value for our PLX cells to treat
millions of patients suffering from peripheral artery disease
(PAD), inflammatory bowel disease (IBD), and multiple sclerosis
(MS).
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a bio-therapeutics
company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe
degenerative, ischemic and autoimmune disorders. The Company is
developing a pipeline of products, stored ready-to-use, that are
derived from human placenta, a non-controversial, non-embryonic,
adult stem cell source.
These placental adherent stromal cells (ASCs) are
expanded in the Company's proprietary PluriXTM 3D
bioreactor, which imitates the natural 3D microenvironment of
these cells and does not require supplemental growth factors or
other exogenous materials. Pluristem believes that the resultant
PLX (PLacental eXpanded) cell’s efficacy may be related to the
secretion of cytokines or other potent immune modulators.
Furthermore, PLX cells are immune privileged and have
immunomodulatory properties, thus protecting the recipient from
immunological reactions that often accompany transplantations.
Pluristem's first product in development, PLX-PAD,
is intended to improve the quality of life of millions of people
suffering from peripheral artery disease (PAD). The Company's
products in development also include PLX-IBD, targeting
Inflammatory Bowel Disease (IBD); PLX-MS, targeting Multiple
Sclerosis; PLX-BMT, targeting the global shortfall of matched
tissue for bone marrow transplantation (BMT) by improving the
engraftment of hematopoietic stem cells (HSCs) contained in
umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.
Pluristem has offices in the USA with research
and manufacturing facilities in Israel.
See our product animation on YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us
About the Rodman & Renshaw 10th
Annual Healthcare Conference
Presented by Rodman & Renshaw LLC
November 10-12, 2008 @ the New York Palace Hotel
455 Madison Avenue
New York, NY 10022
The conference will host more than 550 companies from across the
globe presenting to over 1000 registered institutional
investors.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and federal
securities laws. For example, when we say that our PLX cells
have potential value to treat millions of patients suffering
from peripheral artery disease (PAD), inflammatory bowel disease
(IBD), and multiple sclerosis (MS), we are using forward-looking
statements. These forward-looking statements are based on the
current expectations of the management of Pluristem only, and
are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described
in the forward-looking statements. The following factors, among
others, could cause actual results to differ materially from
those described in the forward-looking statements: failure to
obtain required regulatory approvals, changes in technology and
market requirements; our technology may not be validated as we
progress further and our methods may not be accepted by the
scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with
our process; results in the laboratory may not translate to
equally good results in real surgical settings; our patents may
not be sufficient; our products may harm recipients; changes in
legislation; inability to timely develop and introduce new
technologies, products and applications; loss of market share
and pressure on pricing resulting from competition, which could
cause the actual results or performance of Pluristem to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to
these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence
of unanticipated events. For a more detailed description of the
risk and uncertainties affecting Pluristem, reference is made to
Pluristem's reports filed from time to time with the Securities
and Exchange Commission.
Pluristem Investor Contact:
William Prather RPh, MD
Sr. VP Corporate Development
Ph: 303-883-4954
bill@pluristem.com
Source:
Pluristem Therapeutics Inc.
